This may be due to the fact that different molecular backgrounds (Supplementary Table 2) define sensitivity, such as is apparent clinically with the contrasting responses seen with single agent BRAF inhibitors in melanoma and colorectal cancers (Herr and Brummer, 2015). Here, BRAF is linked to melanoma.